ASOs have been widely applied to NSCLC therapy by targeting key genes regulators of the malignant phenotype, such as B-cell lymphoma 2 (Bcl2), Protein Kinase B (PKB/Akt-1), Kirsten Rat Sarcoma virus (KRAS), Vascular Endothelial Growth Factor (VEGF), Signal Transducer and Activator of Transcription 3 (STAT3), clusterin and Protein Kinase C alpha (PKC alpha). This evidence concerns the gene STAT3 and non-small cell lung carcinoma.